World Heart Corp - WHRT and TSE/WHT Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : World Heart Corp - WHRT and TSE/WHT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dan Hamilton who wrote (66)	12/9/1997 11:51:00 AM
From: Dan Hamilton	Read Replies (1) of 500

World Heart has gotten some coverage in the Financial Post today and other newspapers... Final specifications for HEARTSAVERvad received World Heart Corp Monday Dec 8 1997 Ms Sandy Armstrong reports The company has accepted delivery from the University of Ottawa Heart Institute of the final manufacturing specifications for HEARTSAVERvad left ventricular assist device. After ten years and more than $40 million of research and development investment, manufacturing of the electrohydraulic device will commence in January 1998. HEARTSAVERvad is the first pulsatile ventricular assist device that is fully implantable in the human chest. The device is powered by a patented transcutaneous energy transfer (TET) system and monitored and controlled by a proprietary biotelemetry system. TET transfers electrical power into the device from outside the body without skin perforations. Biotelemetry transfers information about the operation of the heart and the device from inside the body, and receives information from outside the body, permitting the device to be monitored and controlled remotely from any location. HEARTSAVERvad is designed for long term use by people who suffer from inadequate capacity of their natural heart to pump sufficient blood to support normal life activity. HEARTSAVERvad assists the natural heart and can replace part or all of the pumping function. Preclinical trials will be conducted during 1998 and 1999 at the University of Ottawa Heart Institute, the Cleveland Clinic and other leading clinics in Europe and the US. First human use is expected in 1999 in Canada. HEARTSAVERvad and its related TET and biotelemetry technologies are the result of decades of work by scientists in many countries and by the Canadian Artificial Heart Program. This program was centred in the University of Ottawa Heart Institute and supported by many academic and commercial organizations over the past decade. Financing for the program has been supplied by the governments of Canada and Ontario, industrial partners and charitable contributions. In 1996 WorldHeart contracted with the University of Ottawa Heart Institute to provide financing for continued research and development by the Cardiovascular Devices division of the Institute and for commercialization of the products, in return for exclusive worldwide rights to the products. HEARTSAVERvad research and development will continue at the University of Ottawa Heart Institute to support the preclinical and clinical trial activities and to enhance the products for the future. The research and development program has been directed since 1989 by Dr Tofy Mussivand, the inventor of HEARTSAVERvad. Dr Mussivand is director of the Cardiovascular Devices division of the institute and since May 1996 has been president of World Heart. WorldHeart will commence production of HEARTSAVERvad at its new facility in Ottawa in January 1998. Initial products are scheduled for completion during the first quarter, and will be used in preclinical trials during 1998. The first human use of HEARTSAVERvad is scheduled for 1999. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next